Stocks
Polaryx Therapeutics, Inc.PLYX
NASDAQHealthcareBiotechnology$1.85
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted therapies for rare and debilitating diseases, with a lead pipeline focused on genetic medicines. Investors track PLYX for its proprietary lipid nanoparticle delivery platform and upcoming Phase 2 data readouts in 2025.
52W Range: $1.83-$48.91
Congressional Interest in Polaryx Therapeutics, Inc. (PLYX)
No congressional trades have been disclosed for Polaryx Therapeutics, Inc. (PLYX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PLYX?
No congressional trades found for this stock.